phrykt

Faeth Therapeutics, Inc. (FTH): who owns it and who trades it

As of Nov 16, 2026, FTH insiders reported 36 open-market sales worth $1.5M and 49 purchases worth $2.5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cambrian BioPharma Inc (10% owner), with $788K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Faeth Therapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns FTH

44 funds and institutions reported FTH shares worth $326M at the end of Q2 2026, about 50% of the company. The largest holder is Montanova Capital, LLC with 7.8%.

Funds and institutions (13F) 50%Everyone else 50%

10 largest owners, by share of the company

Montanova Capital, LLC7.8%
Avoro Capital Advisors LLC5.6%
Baker Bros. Advisors LP5.0%
Balyasny Asset Management L.P.4.0%
Ra Capital Management, L.P.2.8%
Vivo Capital, LLC2.8%
Logos Global Management LP2.8%
Fairmount Funds Management LLC2.8%
Caligan Partners LP2.4%
B Group, Inc.2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Montanova Capital, LLC2.02M7.82%$50.5M+5747%
Avoro Capital Advisors LLC1.44M5.59%$36.1MNew
Baker Bros. Advisors LP1.29M4.98%$32.2MNew
Balyasny Asset Management L.P.1.04M4.03%$26.1M+6331%
Ra Capital Management, L.P.722,0202.79%$18.1MNew
Vivo Capital, LLC722,0202.79%$18.1MNo change
Logos Global Management LP722,0202.79%$18.1M+2307%
Fairmount Funds Management LLC722,0202.79%$18.1MNew
Caligan Partners LP629,4672.44%$15.7M+400%
B Group, Inc.610,1692.36%$15.3MNew
Trails Edge Capital Partners, LP515,3351.99%$12.9M+312%
Franklin Resources Inc494,5161.91%$12.4M+270%
ADAR1 Capital Management, LLC361,0101.40%$9MNew
Octagon Capital Advisors LP361,0101.40%$9MNew
Marshall Wace, LLP206,5080.80%$5.2M+214%
Boxer Capital Management, LLC180,5050.70%$4.5MNew
Patient Square Capital LP175,0500.68%$4.4MNew
Alyeska Investment Group, L.P.144,4040.56%$3.6MNew
Affinity Asset Advisors, LLC144,4040.56%$3.6MNew
Boothbay Fund Management, LLC133,6430.52%$3.3M+412%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, FTH insiders reported $2.5M of open-market purchases and $1.5M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$2.5M
49 trades, 4 people
Sales, 12 months
$1.5M
36 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 1, 2026
Filed Jul 1, 2026

Purchases and sales by month

$1.1M$1.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 1, 2026Brian C StephensonCFOPurchase600$24.22$14.5KForm 4
Jul 1, 2026Brian C StephensonCFOPurchase4,400$23.40$103KForm 4
Jun 30, 2026Brian C StephensonCFOPurchase1,638$23.88$39.1KForm 4
Jun 30, 2026Brian C StephensonCFOPurchase1,910$22.95$43.8KForm 4
Jun 30, 2026Brian C StephensonCFOPurchase4,255$24.98$106KForm 4
Jun 29, 2026Brian C StephensonCFOPurchase831$23.34$19.4KForm 4
Jun 26, 2026Brian C StephensonCFOPurchase100$26.39$2.6KForm 4
Jun 26, 2026Brian C StephensonCFOPurchase1,358$25.55$34.7KForm 4
Jun 26, 2026Brian C StephensonCFOPurchase4,212$24.90$105KForm 4
Jun 26, 2026Brian C StephensonCFOPurchase580$23.61$13.7KForm 4
Jun 24, 2026Brian C StephensonCFOPurchase100$27.77$2.8KForm 4
Jun 24, 2026Brian C StephensonCFOPurchase3,400$26.98$91.7KForm 4
Jun 24, 2026Brian C StephensonCFOPurchase3,000$25.98$77.9KForm 4
Jun 24, 2026Brian C StephensonCFOPurchase2,891$25.22$72.9KForm 4
Jun 23, 2026Brian C StephensonCFOPurchase6,836$24.12$165KForm 4
Jun 23, 2026Brian C StephensonCFOPurchase1,969$24.84$48.9KForm 4
Jun 23, 2026Brian C StephensonCFOPurchase425$25.91$11KForm 4
Jun 22, 2026Brian C StephensonCFOPurchase1,118$20.82$23.3KForm 4
Jun 22, 2026Brian C StephensonCFOPurchase1,583$22.40$35.5KForm 4
Jun 22, 2026Brian C StephensonCFOPurchase3,329$23.28$77.5KForm 4
Jun 22, 2026Brian C StephensonCFOPurchase356$23.95$8.5KForm 4
Jun 22, 2026Brian C StephensonCFOPurchase1,797$20.23$36.4KForm 4
Jun 22, 2026Anand Kiran ParikhCEOPurchase2,806$19.76$55.4KForm 4
Jun 1, 2026Cambrian BioPharma Inc10% ownerSale24,524$20.00$490KForm 4
Jun 1, 2026Cambrian BioPharma Inc10% ownerSale476$21.14$10.1KForm 4
Apr 7, 2026Ics Opportunities Ii Llc +310% ownerPurchase1,108$33.38$37KForm 4
Apr 7, 2026Ics Opportunities Ii Llc +310% ownerSale2,115$28.94$61.2KForm 4
Apr 7, 2026Ics Opportunities Ii Llc +310% ownerSale205$29.71$6.1KForm 4
Apr 7, 2026Ics Opportunities Ii Llc +310% ownerSale4,423$31.38$139KForm 4
Apr 7, 2026Ics Opportunities Ii Llc +310% ownerSale300$32.25$9.7KForm 4
Apr 7, 2026Ics Opportunities Ii Llc +310% ownerSale1,108$33.38$37KForm 4
Apr 6, 2026Ics Opportunities Ii Llc +310% ownerSale45$31.96$1.4KForm 4
Apr 6, 2026Ics Opportunities Ii Llc +310% ownerSale1,214$31.02$37.7KForm 4
Apr 6, 2026Ics Opportunities Ii Llc +310% ownerPurchase1,104$31.02$34.2KForm 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerSale1,134$34.80$39.5KForm 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerSale374$33.35$12.5KForm 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerSale1,794$32.60$58.5KForm 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerSale1,265$31.75$40.2KForm 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerSale3,099$30.86$95.6KForm 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerPurchase1,276$34.75$44.3KForm 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerPurchase26$33.47$870Form 4
Apr 2, 2026Ics Opportunities Ii Llc +310% ownerPurchase701$35.55$24.9KForm 4
Apr 1, 2026Millennium Management Llc +310% ownerPurchase1,613$34.59$55.8KForm 4
Apr 1, 2026Millennium Management Llc +310% ownerPurchase1,161$31.53$36.6KForm 4
Apr 1, 2026Millennium Management Llc +310% ownerSale46$34.75$1.6KForm 4
Apr 1, 2026Millennium Management Llc +310% ownerSale1,104$31.52$34.8KForm 4
Apr 1, 2026Millennium Management Llc +310% ownerPurchase3,401$35.46$121KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerPurchase186$30.48$5.7KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerPurchase616$24.69$15.2KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerPurchase1,770$25.32$44.8KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerPurchase1,048$26.73$28KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerPurchase17$27.78$472Form 4
Mar 31, 2026Millennium Management Llc +310% ownerPurchase1,957$31.45$61.5KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerPurchase411$32.60$13.4KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerSale191$24.28$4.6KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerSale1,251$25.17$31.5KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerSale57$27.11$1.5KForm 4
Mar 31, 2026Millennium Management Llc +310% ownerSale5$28.41$142Form 4
Mar 31, 2026Millennium Management Llc +310% ownerSale87$31.52$2.7KForm 4
Mar 30, 2026Ics Opportunities Ii Llc +310% ownerSale518$25.85$13.4KForm 4
Mar 30, 2026Ics Opportunities Ii Llc +310% ownerSale370$27.68$10.2KForm 4
Mar 30, 2026Ics Opportunities Ii Llc +310% ownerPurchase2,992$25.08$75KForm 4
Mar 30, 2026Ics Opportunities Ii Llc +310% ownerPurchase4,995$25.99$130KForm 4
Mar 30, 2026Ics Opportunities Ii Llc +310% ownerPurchase1,176$26.70$31.4KForm 4
Mar 30, 2026Ics Opportunities Ii Llc +310% ownerPurchase370$27.68$10.2KForm 4
Mar 27, 2026Ics Opportunities Ii Llc +310% ownerPurchase10,643$26.29$280KForm 4
Mar 27, 2026Ics Opportunities Ii Llc +310% ownerPurchase4,384$27.28$120KForm 4
Mar 27, 2026Ics Opportunities Ii Llc +310% ownerPurchase294$28.13$8.3KForm 4
Mar 27, 2026Ics Opportunities Ii Llc +310% ownerSale469$26.77$12.6KForm 4
Mar 27, 2026Ics Opportunities Ii Llc +310% ownerSale36$27.37$985Form 4
Mar 26, 2026Ics Opportunities Ii Llc +310% ownerPurchase1,327$27.95$37.1KForm 4
Mar 26, 2026Ics Opportunities Ii Llc +310% ownerPurchase2,601$28.85$75KForm 4
Mar 26, 2026Ics Opportunities Ii Llc +310% ownerPurchase1,025$29.98$30.7KForm 4
Mar 26, 2026Ics Opportunities Ii Llc +310% ownerSale583$26.88$15.7KForm 4
Mar 26, 2026Ics Opportunities Ii Llc +310% ownerSale1,274$28.69$36.6KForm 4
Mar 26, 2026Ics Opportunities Ii Llc +310% ownerPurchase778$27.23$21.2KForm 4
Dec 9, 2025Cambrian BioPharma Inc10% ownerSale3,105$8.59$26.7KForm 4
Dec 9, 2025Cambrian BioPharma Inc10% ownerSale446$7.92$3.5KForm 4
Dec 9, 2025Cambrian BioPharma Inc10% ownerSale395$8.04$3.2KForm 4
Dec 9, 2025Cambrian BioPharma Inc10% ownerSale2,666$7.95$21.2KForm 4
Dec 8, 2025James Peyer10% ownerSale3,105$8.59$26.7KForm 4
Dec 5, 2025Cambrian BioPharma Inc10% ownerSale14,508$11.40$165KForm 4
Dec 5, 2025Cambrian BioPharma Inc10% ownerSale42$13.16$553Form 4
Dec 5, 2025Cambrian BioPharma Inc10% ownerSale1,745$12.29$21.4KForm 4
Dec 4, 2025Cambrian BioPharma Inc10% ownerSale5,000$9.06$45.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ics Opportunities Ii Llc10% owner$960K$627KApr 7, 2026
Brian C StephensonChief Financial Officer$1.1M–Jul 1, 2026
Cambrian BioPharma Inc10% owner–$788KJun 1, 2026
Millennium Management Llc10% owner$382K$77KApr 1, 2026
Anand Kiran ParikhPresident and CEO, Director$55.4K–Jun 22, 2026
James Peyer10% owner–$26.7KDec 8, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

FTH short interest

High short interest. 10.6% of FTH shares are sold short: about 1 share in 9. Over the last 9 reports the number of shares short went up 250%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.73M FTH shares were sold short, 10.6% of the shares outstanding, up 17.7% from the report before. At the average daily volume of 432,468 shares, buying them all back would take about 6.3 trading days (days to cover).

Shares short, % of all shares

10.6%Jun 30Oct 3075.9%

Days to cover

6.3Jun 30Oct 308.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.73M10.57%+18%432,4686.3
Oct 15, 20262.32M8.98%+12%297,8207.8
Sep 30, 20262.07M8.00%+57%569,3893.6
Sep 15, 20261.32M5.10%+20%301,7834.4
Aug 31, 20261.10M4.25%+33%299,6213.7
Aug 14, 2026827,1673.20%+1%300,9022.8
Jul 31, 2026815,5873.16%-8%289,9222.8
Jul 15, 2026890,30666.43%+14%235,9503.8
Jun 30, 2026780,39658.23%+27%112,2857.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Faeth Therapeutics company events

Faeth Therapeutics filed 18 reports on Form 8-K in the last 12 months, 9 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementFaeth Therapeutics, Inc. made available a presentation to be used to discuss, among other things, the topline clinical data from the Company’s Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer. Filing
  2. Nov 9, 2026AnnouncementShared information with investors. Filing
  3. Nov 3, 2026ResultsReleased financial results. Filing
  4. Oct 27, 2026LeadershipThe Board of Directors of Faeth Therapeutics, Inc. increased the size of the Board from six to seven directors and appointed Adam Schayowitz to serve as a Class III director, effective immediately. Filing
  5. Sep 17, 2026LeadershipThe Board of Directors of Faeth Therapeutics, Inc. increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately. Filing
  6. Aug 4, 2026ResultsReleased financial results. Filing
  7. Jul 23, 2026LeadershipThe Board of Directors of Faeth Therapeutics, Inc., upon the recommendation of the Compensation Committee of the Board, approved one-time supplemental grants of performance-based stock options under the Company’s 2026 Equity Incentive Plan to current employees of the Company who were employed with… Filing
  8. Jun 18, 2026AgreementFaeth Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC, pursuant to which the Company from time to time may offer and sell shares of its common stock, par value $0.0001 per share, through or to the Agent. Filing
  9. Jun 15, 2026LeadershipDeparture of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  10. Jun 10, 2026LeadershipSensei Biotherapeutics, Inc. held its 2026 annual meeting of stockholders. Filing
  11. May 22, 2026AnnouncementSensei Biotherapeutics, Inc. announced an update regarding the expected reconstitution of the board of directors of the Company in connection with the Company’s 2026 Annual Meeting of Stockholders to be held on June 10, 2026, as described in the Company’s definitive proxy statement filed with the… Filing
  12. May 21, 2026AnnouncementAs previously announced, Sensei Biotherapeutics, Inc. will hold its 2026 annual meeting of stockholders of the Company on June 10, 2026, at 11:00 a.m. Filing
  13. May 15, 2026ResultsReleased financial results. Filing
  14. Apr 16, 2026LeadershipEach of Christopher W. Gerry, Thomas Ricks, and Kristian Humer tendered conditional resignations from the Board of Directors of Sensei Biotherapeutics, Inc., in each case effective as of two business days following the conclusion of the Company’s Annual Meeting of Stockholders to be held on June… Filing
  15. Mar 30, 2026ResultsReleased financial results. Filing
  16. Feb 18, 2026LeadershipAppointment of Directors In accordance with the Merger Agreement, on February 17, 2026, effective immediately after the First Effective Time, Anand Parikh was appointed to the Board as a Class I director of the Board. Filing
  17. Feb 13, 2026LeadershipThe board of directors of Sensei Biotherapeutics, Inc. voted to increase the size of the Board from three members to five members and to appoint Christopher W. Gerry and Phillip B. Donenberg as new directors to fill the resulting vacancy, effective immediately, for a term until each of their… Filing
  18. Dec 23, 2025LeadershipSensei Biotherapeutics, Inc. entered into Retention Agreements with Christopher Gerry, its President and Principal Executive Officer, and Josiah Craver, its Senior Vice President of Finance and Principal Finance and Accounting Officer, which amend in part the compensatory provisions of their… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Faeth Therapeutics financials

Famous investors that hold FTH

3 of the 50 well-known investors we track reported holding FTH in their latest 13F filing. The largest position is Ken Griffin's, worth $13.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026450,626$13.4M0.0%+3565%
Israel Englander · Millennium ManagementQ3 202629,002$863K0.0%New
Jim Simons · Renaissance TechnologiesQ3 20268,725$259K0.0%-57%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named FTH in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Avoro Capital Advisors LLC13G5.5%
Nov 16, 2026Avoro Capital Advisors LLC13G5.5%
Nov 13, 2026Montanova Capital, LLC13G/A8.9%
Nov 13, 2026Montanova Capital, LLC13G/A8.9%

Questions about Faeth Therapeutics, Inc. (FTH) stock

Who owns the most FTH stock?

The largest reported owner of Faeth Therapeutics, Inc. (FTH) is Montanova Capital, LLC, with 7.8% of the company. In total, 44 funds and institutions reported holding FTH at the end of Q2 2026, together about 50% of the shares. See the largest owners.

Are FTH insiders buying or selling?

In the last 12 months, FTH insiders reported 49 open-market purchases worth $2.5M and 36 sales worth $1.5M. The latest trade was on Jul 1, 2026. See every trade.

What is the short interest in FTH?

As of Oct 30, 2026, 2.73M FTH shares were sold short, 10.6% of the shares outstanding, up 17.7% from the report before. At the average daily volume of 432,468 shares, buying them all back would take about 6.3 trading days (days to cover). See the history.

Which famous investors hold FTH?

3 of the 50 well-known investors we track reported FTH in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $13.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.